AbbVie To Create New Global Aesthetics Business
AbbVie, upon completing its $63-billion acquisition of Allergan, plans to create a new global business, Allergan Aesthetics, which will include Allergan’s Botox and related products. The new business will become effective upon the expected first-quarter 2020 close of the Allergan acquisition.
Allergan Aesthetics will operate as a new global dedicated business with its own research and development function under the AbbVie umbrella and will include aesthetic products including, Botox Cosmetic, the Juvederm collection of dermal fillers, and Coolsculpting body contouring products.
This global business to be located in Irvine, California, will be led by Carrie Strom, currently Senior Vice President, US Medical Aesthetics, Allergan. Upon completion of the Allergan acquisition, Ms. Strom will be named Senior Vice President, AbbVie and President, Global Allergan Aesthetics. She will oversee the worldwide operations, along with a team of current Allergan leaders and report directly to Richard A. Gonzalez, Chairman and Chief Executive Officer, AbbVie.
The Eye Care and Specialty businesses, which will include Botox (therapeutics) and products for central nervous system diseases, women’s health product, and drugs for gastrointestinal diseases, will be integrated into the existing AbbVie organization. Several Allergan leaders have accepted leadership positions in the future company across these franchises, according to AbbVie.